IceCure Medical reported approximately 45% revenue growth in Q2 2026, driven by increased system sales and disposable probe utilization. The company's U.S. commercial footprint expanded by about 70% following FDA clearance for early-stage low-risk breast cancer, and gross margin improved to 30% despite unfavorable foreign exchange fluctuations. Management expects to enroll the first patients in the CHOICE study within 3 to 4 weeks and remains on track to meet the FDA-mandated hurdle of 80 patients treated by March 2027. The company completed a financing round in the second quarter, raising approximately $8.5 million in gross profit to strengthen the balance sheet.
Icecure MedicalQ2 revenue growth, margin improvement, and financing round strengthen financials.
NVIDIA Corporation